Current guidelines recommend that all patients with adenocarcinomas be tested for routine biomarkers, including EGFR mutations, ALK rearrangement, and ROS1 rearrangement, because FDA-approved agents for lung cancer are available for these biomarkers8,18. This evidence concerns the gene ROS1 and lung carcinoma.